Soluble Vascular Endothelial Growth Factor Receptor-2 and Inflammatory Factors in Macular Edema with Branch Retinal Vein Occlusion

被引:42
作者
Noma, Hidetaka [1 ]
Funatsu, Hideharu [1 ]
Mimura, Tatsuya [2 ]
Eguchi, Shuichiro [3 ]
Hori, Sadao [4 ]
机构
[1] Tokyo Womens Med Univ, Yachiyo Med Ctr, Dept Ophthalmol, Chiba 2768524, Japan
[2] Univ Tokyo, Dept Ophthalmol, Grad Sch Med, Tokyo 113, Japan
[3] Eguchi Eye Hosp, Dept Ophthalmol, Hakodate, Hokkaido, Japan
[4] Tokyo Womens Med Univ, Dept Ophthalmol, Tokyo, Japan
关键词
NF-KAPPA-B; INTRAVITREAL BEVACIZUMAB; VITREOUS LEVELS; LASER TREATMENT; ACTIVATION; EXPRESSION; INHIBITOR; CYTOKINES; VEGFR-2; PHOSPHORYLATION;
D O I
10.1016/j.ajo.2011.04.006
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
PURPOSE: To investigate relationships among vitreous fluid levels of soluble vascular endothelial growth factor receptor-2 (sVEGFR-2), vascular endothelial growth factor (VEGF), and soluble intercellular adhesion molecule 1 (sICAM-1) in patients with branch retinal vein occlusion (BRVO) and macular edema or patients with idiopathic macular hole. DESIGN: Retrospective case-control study. METHODS: SETTING: Tokyo Women's Medical University and Eguchi Eye Hospital. PATIENT POPULATION: Forty-nine Japanese patients who underwent unilateral vitrectomy (27 with BRVO and 22 with macular hole). OBSERVATION PROCEDURES: Vitreous fluid samples were obtained during vitreoretinal surgery to measure the levels of sVEGFR-2, VEGF, and sICAM-1. Retinal ischemia was evaluated from capillary nonperfusion on fluorescein angiography. Macular edema was examined by optical coherence tomography. MAIN OUTCOME MEASURES: Vitreous fluid levels of the 3 molecules and severity of macular edema. RESULTS: BRVO patients had a significantly higher vitreous fluid level of sVEGFR-2 (median, 1670 pg/mL; interquartile range [IQL], 1205 to 2225 pg/mL) than macular hole patients (median, 1265 pg/mL; IQR, 731 to 1800 pg/mL; P = .017), as was the case for VEGF (median, 237 pg/mL; IQR, 42.2 to 1305 pg/mL; vs median, 15.6 pg/mL; IQR, 15.6 to 15.6 pg/mL; P < .001) and sICAM-1 (median, 10.1 ng/mL; IQR, 6.3 to 22.5 ng/mL; vs median, 4.1 ng/mL; IQR, 3.3 to 6.0 ng/mL; P < .001). In BRVO patients, there was a significant positive correlation between vitreous fluid levels of sVEGFR-2 or VEGF and sICAM-1, but not between sVEGFR-2 and VEGF. Vitreous fluid levels of all 3 molecules were correlated significantly the with severity of macular edema in BRVO patients. CONCLUSIONS: sVEGFR-2 may induce an increase of vascular permeability together with or via sICAM-1, or both with and via sICAM-1, in BRVO patients with macular edema. (Am J Ophthalmol 2011;152:669-677. (C) 2011 by Elsevier Inc. All rights reserved.)
引用
收藏
页码:669 / 677
页数:9
相关论文
共 43 条
[1]   Predictive factors for changes in macular edema in intravitreal bevacizumab therapy of retinal vein occlusion [J].
Ach, Thomas ;
Hoeh, Alexandra E. ;
Schaal, Karen B. ;
Scheuerle, Alexander F. ;
Dithmar, Stefan .
GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 2010, 248 (02) :155-159
[2]   VASCULAR ENDOTHELIAL GROWTH-FACTOR IN OCULAR FLUID OF PATIENTS WITH DIABETIC-RETINOPATHY AND OTHER RETINAL DISORDERS [J].
AIELLO, LP ;
AVERY, RL ;
ARRIGG, PG ;
KEYT, BA ;
JAMPEL, HD ;
SHAH, ST ;
PASQUALE, LR ;
THIEME, H ;
IWAMOTO, MA ;
PARK, JE ;
NGUYEN, HV ;
AIELLO, LM ;
FERRARA, N ;
KING, GL .
NEW ENGLAND JOURNAL OF MEDICINE, 1994, 331 (22) :1480-1487
[3]  
[Anonymous], 1984, AM J OPHTHALMOL, V98, P271
[4]  
Arnarsson A, 2000, INVEST OPHTH VIS SCI, V41, P877
[5]  
Boyle EM, 1998, CIRCULATION, V98, pII282
[6]   Ranibizumab for macular edema due to retinal vein occlusions: Implication of VEGF as a critical stimulator [J].
Campochiaro, Peter A. ;
Hafiz, Gulnar ;
Shah, Syed Mahmood ;
Nguyen, Quan Dong ;
Ying, Howard ;
Do, Diana V. ;
Quinlan, Edward ;
Zimmer-Galler, Ingrid ;
Haller, Julia A. ;
Solomon, Sharon D. ;
Sung, Jennifer U. ;
Hadi, Yasmin ;
Janjua, Kashif A. ;
Jawed, Nida ;
Choy, David F. ;
Arron, Joseph R. .
MOLECULAR THERAPY, 2008, 16 (04) :791-799
[7]   Ranibizumab for Macular Edema following Branch Retinal Vein Occlusion Six-Month Primary End Point Results of a Phase III Study [J].
Campochiaro, Peter A. ;
Heier, Jeffrey S. ;
Feiner, Leonard ;
Gray, Sarah ;
Saroj, Namrata ;
Rundle, Amy Chen ;
Murahashi, Wendy Yee ;
Rubio, Roman G. .
OPHTHALMOLOGY, 2010, 117 (06) :1102-U111
[8]  
Chalmers J, 1999, J HYPERTENS, V17, P151
[9]   Signal transduction by vascular endothelial growth factor receptors [J].
Claesson-Welsh, L .
BIOCHEMICAL SOCIETY TRANSACTIONS, 2003, 31 :20-24
[10]   The biology of vascular endothelial growth factor [J].
Ferrara, N ;
DavisSmyth, T .
ENDOCRINE REVIEWS, 1997, 18 (01) :4-25